S6
S66.AU Star Combo Pharma Ltd
- Market cap
- AUD 18.9M
- P/E
- -
- P/B
- 0.49x
- ROE
- 1.0%
- Dividend yield
- 2.11%
- Fundamental score
- 1.6/5
Ratios use the latest price and the fiscal year ending Jun 2026.
Is S66.AU undervalued?
Graham numberThe Graham number of Star Combo Pharma Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Star Combo Pharma Ltd fundamental analysis
8 of 22 checks passedROE 0/2
Low return on equity (1.0%), below 10%.
ROA 1/1
Return on assets (0.8%) is above the industry median (-30.2%).
Profit Consistency 1/2
Profitable for 3 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 0/1
Last year's EPS growth (-92.5%) is below the industry median (-11.1%).
Revenue Growth 0/2
Revenue shrank 1.5% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (10.8%), 40% or less.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Debt Coverage 1/1
Operating cash flow covers 20% of total debt.
Interest Coverage 0/1
EBIT is negative, against interest expense, below 5x.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 1/1
Price to book (0.5x) is below the industry median (6.8x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
Dividend yield cannot be calculated.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
Payout ratio is 126.7%, above 90% of earnings.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Star Combo Pharma Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Star Combo Pharma Ltd
Star Combo Pharma Limited manufactures and distributes health food products and nutritional supplements in Australia and China. It operates in two segments, OEM and Retail. The company engages in the development, manufacturing, marketing, and sale of natural health supplements and skin care products and provision of Chinese health products through its e-commerce platform. It sells its products under the Living Healthy, Costar, Amax, and J&K brands. Star Combo Pharma Limited …
Full company profileStar Combo Pharma Ltd financial statements
Star Combo Pharma Ltd annual financial statements
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 9.79M | 10.7M | 21.4M | 38.8M | 26.7M | 22.9M | 24.7M | 26.0M | 27.8M | 23.6M |
| Gross Profit | 3.94M | 4.58M | 3.68M | 5.29M | 4.61M | 5.61M | 4.66M | 5.44M | 6.27M | 4.99M |
| Operating Income | 2.58M | -2.07M | -2.31M | -513K | -2.23M | -446K | 962K | 723K | -238K | -231K |
| EBITDA | 2.72M | -1.46M | -1.93M | 352K | -6.40M | -127K | -2.53M | 2.24M | 6.99M | 1.24M |
| Net Income | 1.64M | -1.97M | -1.73M | -349K | -7.88M | -696K | -4.00M | 747K | 5.25M | 395K |
| EPS | 0.02 | -0.03 | -0.02 | 0.00 | -0.06 | -0.01 | -0.03 | 0.01 | 0.04 | 0.00 |
| Balance Sheet | ||||||||||
| Total Assets | 19.3M | 19.0M | 27.5M | 54.7M | 43.3M | 43.4M | 42.2M | 42.8M | 48.5M | 50.1M |
| Total Liabilities | 3.64M | 2.78M | 7.51M | 10.2M | 7.13M | 8.04M | 8.97M | 9.30M | 10.2M | 11.3M |
| Shareholders' Equity | 15.7M | 16.3M | 20.0M | 44.5M | 36.2M | 35.4M | 33.1M | 33.3M | 38.1M | 38.8M |
| Cash & Short-term Investments | 10.2M | 8.94M | 4.62M | 26.6M | 17.3M | 10.4M | 9.49M | 7.36M | 18.1M | 18.0M |
| Total Debt | 1.62M | 136K | 57.9K | 5.61M | 3.30M | 4.12M | 4.19M | 4.03M | 3.93M | 4.19M |
| Cash Flow | ||||||||||
| Operating Cash Flow | 932K | -1.84M | -2.19M | -1.02M | 332K | 87.1K | 1.88M | -316K | 11.9M | 3.28M |
| Capital Expenditure | 261K | 199K | 4.24M | 2.78M | 7.26M | 7.29M | 2.73M | 1.44M | 394K | 2.45M |
| Free Cash Flow | 671K | -2.04M | -6.42M | -3.80M | -6.93M | -7.21M | -852K | -1.76M | 11.5M | 823K |
| Ratios | ||||||||||
| ROE | 10.4% | -12.1% | -8.6% | -0.8% | -21.8% | -2.0% | -12.1% | 2.2% | 13.8% | 1.0% |
| ROA | 8.5% | -10.4% | -6.3% | -0.6% | -18.2% | -1.6% | -9.5% | 1.7% | 10.8% | 0.8% |
| Net Profit Margin | 16.7% | -18.4% | -8.1% | -0.9% | -29.5% | -3.0% | -16.2% | 2.9% | 18.9% | 1.7% |
| Debt to Equity | 0.10x | 0.01x | 0.00x | 0.13x | 0.09x | 0.12x | 0.13x | 0.12x | 0.10x | 0.11x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Star Combo Pharma Ltd dividends
- Dividend yield
- 2.11%
- Forward dividend
- -
- Payout ratio
- 126.7%
- Ex-dividend date
- Oct 13, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | 500K | 0.00 | 126.7% |
| 2025 | 500K | 0.00 | 9.5% |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | AUD 2.06M | 0.02 | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Star Combo Pharma Ltd
- Insiders 91.25%
- Institutions 2.62%
- Public & others 6.13%
- Shares outstanding 135M
- Free float 11.8M
Star Combo Pharma Ltd company profile
- Company name
- Star Combo Pharma Ltd
- Ticker
- S66.AU
- ISIN
- AU0000004798
- Exchange
- Australian Securities Exchange
- Sector
- Consumer Defensive
- Industry
- Personal Care Products
- Fiscal year end
- June
- Address
- 171-177 Woodpark Road, Smithfield, NSW, Australia, 2164
- Phone
- 61 2 9756 6555
- Website
- starcombo.com.au
About Star Combo Pharma Ltd
Star Combo Pharma Limited manufactures and distributes health food products and nutritional supplements in Australia and China. It operates in two segments, OEM and Retail. The company engages in the development, manufacturing, marketing, and sale of natural health supplements and skin care products and provision of Chinese health products through its e-commerce platform. It sells its products under the Living Healthy, Costar, Amax, and J&K brands. Star Combo Pharma Limited was founded in 2004 and is based in Smithfield, Australia.
Star Combo Pharma Ltd management
5- Ms. Su Zhang M.B.A.CEO & Executive Director
- Mr. JinXing Zhang B.S.Founder, MD & Director
- Mr. James NiChief Financial Officer
- He Ben B.S.Chief Operating Officer
- Mr. Patrick James Raper F.A.C.I.D., FAICD, FCPACompany Secretary